Text Size

Eyedrops containing SA9000 prodrugs result in sustained reductions in intraocular pressure in rabbits

Arnold J.J., Choksi Y., Chen X., Shimazaki A., Hatten J., Toone E.J., Epstein D.L., Challa P.


  • 2009
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Preclinical development

  • Affiliations

    Department of Ophthalmology, Duke University School of Medicine, Duke University, Durham, NC, United States; Department of Chemistry, Duke University School of Medicine, Duke University, Durham, NC, United States; Santen Pharmaceutical Co Ltd., Tokyo, Japan; Department of Pharmaceutical, Social, and Administrative Sciences, Samford University McWhorter School of Pharmacy, Birmingham, AL, United States; Duke Eye Center, Box 3802 DUMC, Durham, NC 27710, United States

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group


Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.


Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022